https://rss.com/podcasts/biopharma-morning-coffee Exactly what it means - get a cup of coffee, listen to a brief rundown of latest biopharma news - but not just in a "here's what happened" way - get extra insights WHY these news matter.

]]> RSS.com 2026.401.141116 Fri, 17 Apr 2026 15:23:46 GMT en a92eb007-af83-54ce-98a9-8228b599baa5 https://media.rss.com/biopharma-morning-coffee/20260226_070255_730ad3b788c2188ddc719fddc27b5622.png https://rss.com/podcasts/biopharma-morning-coffee yes Pavel Ryzhov Pavel Ryzhov false episodic podcast United States, USA Gilead's $7.8B acquisition of Arcellx and its CAR-T therapy anito-cel headlines this week — a PDUFA date of December 2026 signals a major cell therapy outsourcing wave ahead. The FDA also launched its bespoke gene therapy pathway, opening a new regulatory road for gene editing and RNA-based rare disease treatments. Plus: the GLP-1 war heats up as Novo's CagriSema falls to Zepbound, Pfizer licenses a Chinese GLP-1 for $495M, and Astellas bets $1.7B on a masked T-cell engager for prostate cancer.

]]> https://rss.com/podcasts/biopharma-morning-coffee/2579859 e0b6c9a4-78ef-4bd7-9421-b9fb4980b188 613 full false Thu, 26 Feb 2026 08:20:35 GMT